Schrödinger, Inc. (NASDAQ:SDGR) is a scientific software and biotechnology company that specializes in developing ...

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight ...

Today, we put Schrodinger, Inc. in the spotlight as we do a post fourth quarter results assessment on this intriguing developmental and software concern. The company's core software business continues ...

Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management presented at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc. (NASDAQ:SDGR) from Neutral to Buy, with a $24 price ...

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Schrödinger’s updated analyst framework trims its fair ...

During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery. The company's shares are still up more than 108% so ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...